DYN — Dyne Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1818794 ·
Last close
$16.02
Market Cap
$3.00B
52W High
$27.31
52W Low
$14.00
ADV30
2,674,730
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -197,074,000 -193,552,000 1,234,802,000 913,203,000 303,869,000
Jun 2026 0 — -181,661,000 -178,556,000 994,013,000 676,114,000 291,862,000
Mar 2026 0 — -125,276,000 -120,854,000 1,079,950,000 753,102,000 214,895,000
Dec 2025 0 — -116,129,000 -111,955,000 1,186,958,000 893,369,000 214,829,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-564,529,000
Investing CF
$-7,499,000
Financing CF
$914,243,000
CapEx
$-4,232,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.96
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,889,104,000
Inventory
—
Receivables
—
ST Investments
$221,183,000
EBIT TTM
$-586,977,000
Pretax Income TTM
$-604,917,000
Interest Exp TTM
$17,940,000
Analysts
15

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -468,184,000 -446,214,000 1,186,958,000 214,829,000 972,129,000 -403,207,000
Dec 2024 0 -343,886,000 -317,418,000 691,234,000 61,396,000 629,838,000 -292,369,000
Dec 2023 0 -242,162,000 -235,937,000 165,082,000 73,790,000 91,292,000 -188,158,000
Dec 2022 0 -170,962,000 -168,099,000 306,325,000 53,961,000 252,364,000 -153,645,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-519,406,000
OpCashFlow TTM
—
Assets (Latest)
$994,013,000
Forward EPS
$-3.31

Max Pain — expiry 2026-12-18

max pain strike: $22.50 · spot: $15.87 · call oi: 3,235 · put oi: 7,755
Expected Move to 2026-12-18: ±$2.83 (17.83%) — implied range $13.04 – $18.70 · ATM straddle on $16.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TLX Telix Pharmaceuticals Ltd $3.01B $8.85 —
XERS Xeris Biopharma Holdings, Inc. $3.07B $16.80 —
ZLAB Zai Lab Ltd $2.91B $23.53 —
BGM BGM Group Ltd. $3.09B $8.13 —
LEGN Legend Biotech Corp $3.13B $16.11 —

News headlines (Yahoo Finance, 1h cache)

Dyne Therapeutics to Participate in Upcoming Investor Conference
2026-11-11 12:30 · Yahoo
Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
2026-11-05 20:13 · Yahoo
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-05 12:30 · Yahoo
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-22 20:05 · Yahoo
Why Dyne Therapeutics (DYN) Is Back In The Spotlight
2026-10-07 14:12 · Yahoo
Dyne Therapeutics stock rises on positive DM1 trial results
2026-09-29 21:23 · Yahoo
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
2026-09-29 20:05 · Yahoo
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
2026-09-17 16:13 · Yahoo
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
2026-09-09 15:41 · Yahoo
PepGen Stock Doubles in One Session - Here's Why
2026-11-10 18:47 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.